CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
探索 Teclistamab 的高级别难治性神经毒性：一种报告不足的临床实体
英文原题：Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity.
查看英文原题
Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
靶向B细胞成熟抗原的T细胞重定向双特异性抗体近期已开始用于复发/难治性多发性骨髓瘤的真实世界治疗。尽管尚无头对头比较研究，总体观察显示，与CAR-T 细胞疗法相比，这些药物毒性级别较低。然而，根据我们单中心真实世界经验，接受teclistamab治疗的2例患者出现高级别、难治性免疫效应细胞相关神经毒性综合征（ICANS），对大剂量皮质类固醇或其他免疫抑制治疗等传统毒性缓解策略无应答。随着这类新型重要药物的使用增加，必须保持谨慎。
展开英文摘要原文
T-cell re-directing bispecific antibodies targeting B-cell maturation antigens have recently entered real-world use in relapsed/refractory multiple myeloma. While no head-to-head comparison has been done, they have generally been observed to have lower-grade toxicities compared with their chimeric antigen receptor T-cell (CAR-T) counterparts.
However, in our real-world, single-institution experience, we have encountered two patients receiving teclistamab who experienced high-grade and refractory immune effector cell-associated neurotoxicity syndrome (ICANS) that did not respond to traditional toxicity mitigation strategies of high-dose corticosteroids or other immunosuppressive therapies. As we increase our use of these novel and vital agents, caution must be warranted.
论文信息
- 作者
- Lutfi F、Abdallah AO、Nashatizadeh M、Ahmed N、Nelson M、Hamideh J、Mahmoudjafari Z、Shune L
- 单位
- Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, USA.United States
- 文献类型
- 病例报告
- 期刊
- Cureus2023 Nov
- 原文标识
- PubMed 38130552 · DOI 10.7759/cureus.49192
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →